^
    Back
    Association details:
    Biomarker:MSI-H/dMMR + HER-2 mutation
    Cancer:Colorectal Cancer
    Drug Class:PD1 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    The Oncologist
    Title:

    Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma

    Published date:
    04/12/2021
    Excerpt:
    MSI-H patients with HER2 mutation had significantly worse median progression-free survival for programmed death-1 (PD-1) antibody than those without HER2 alteration (p = .036).
    DOI:
    https://doi.org/10.1002/onco.13786